Onco-Innovations Limited ONNVF
OTC PK
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.22% | -53.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 65.37% | -49.57% | |||
| Operating Income | -68.43% | 50.49% | |||
| Income Before Tax | -122.50% | 50.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -122.50% | 50.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -122.50% | 50.76% | |||
| EBIT | -68.43% | 50.49% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -117.39% | 52.58% | |||
| Normalized Basic EPS | -117.39% | 52.48% | |||
| EPS Diluted | -117.39% | 52.58% | |||
| Normalized Diluted EPS | -117.39% | 52.48% | |||
| Average Basic Shares Outstanding | 2.34% | 3.64% | |||
| Average Diluted Shares Outstanding | 2.34% | 3.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||